https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-12-03 / Front Immunol 2013 Dec;4:417
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-12-03 / Front Immunol 2013 Dec;4:4172013-12-03 00:00:002019-02-15 08:36:00Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-12-01 / Anticancer Res 2013 Dec;33(12):5495-500
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-12-01 / Anticancer Res 2013 Dec;33(12):5495-5002013-12-01 00:00:002024-03-18 10:53:49Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-18 / Front Immunol 2013 Nov;4:382
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-18 / Front Immunol 2013 Nov;4:3822013-11-18 00:00:002020-02-05 10:32:56Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e270592013-11-06 00:00:002021-11-15 13:33:23Dendritic cell-based immunotherapy in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-05 / Autoimmunity 2014 Feb;47(1):46-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-05 / Autoimmunity 2014 Feb;47(1):46-562013-11-05 00:00:002019-02-15 08:45:31Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-01 / Neurosurgery 2013 Nov;73(5):863-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-01 / Neurosurgery 2013 Nov;73(5):863-72013-11-01 00:00:002019-02-15 08:46:26Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-01 / Cancer J 2013 Nov-Dec;19(6):511-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-01 / Cancer J 2013 Nov-Dec;19(6):511-62013-11-01 00:00:002013-11-01 00:00:00Dendritic cells, inflammation, and breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-28 / Pathol. Oncol. Res. 2014 Apr;20(2):357-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-28 / Pathol. Oncol. Res. 2014 Apr;20(2):357-652013-10-28 00:00:002019-02-15 08:45:59Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-24 / J Extracell Vesicles 2013;2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-24 / J Extracell Vesicles 2013;22013-10-24 00:00:002019-02-15 08:46:15Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-21 / Neurol. Med. Chir. (Tokyo) 2013;53(11):741-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-21 / Neurol. Med. Chir. (Tokyo) 2013;53(11):741-542013-10-21 00:00:002019-02-15 08:47:29Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials
